Biohaven Ltd. (BHVN) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
20.12
↑+103% vs avg
5yr avg: 9.91
30Y Low1.2·High23.3
ROE
↓
-310.8%
↑-52% vs avg
5yr avg: -204.7%
30Y Low-342%·High-84%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BHVN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Biohaven Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.0B | $1.2B | $3.4B | $3.0B | $621M | — | — | — |
| Enterprise Value | $1.1B | $1.3B | $3.3B | $2.8B | $450M | — | — | — |
| P/E Ratio → | -1.42 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 20.12 | 23.33 | 8.05 | 7.12 | 1.15 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BHVN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
BHVN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -310.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -310.8% | -310.8% | -198.8% | -84.4% | -180.1% | -249.4% | -342.2% | — |
| ROA | -138.5% | -138.5% | -150.0% | -69.5% | -141.9% | -168.6% | -52.1% | -153.6% |
| ROIC | -242.1% | -242.1% | -232.4% | -113.2% | -218.8% | -1662.6% | — | — |
| ROCE | -187.2% | -187.2% | -192.7% | -84.7% | -169.1% | -240.9% | -63.7% | -172.3% |
BHVN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $49M ($279M total debt minus $230M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.36 | 5.36 | 0.09 | 0.07 | 0.06 | 0.03 | 0.05 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.94 | -0.15 | -0.51 | -0.32 | -0.77 | -1.03 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -42.57 |
BHVN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Biohaven Ltd.'s current ratio of 3.18x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.98x to 3.18x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.18 | 3.18 | 3.49 | 7.98 | 6.52 | 2.26 | 3.00 | 4.96 |
| Quick Ratio | 3.18 | 3.18 | 3.49 | 7.98 | 6.52 | 2.26 | 3.00 | 4.96 |
| Cash Ratio | 2.75 | 2.75 | 3.15 | 6.89 | 5.17 | 1.81 | 2.76 | 4.79 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
BHVN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Biohaven Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $108M | $91M | $71M | $45M | $36M | $36M | $48M |
Peer Comparison
Compare BHVN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BHVNYou | $1B | -1.4 | — | — | — | — | -310.8% | -242.1% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 KALA | $617676 | -0.0 | — | — | — | — | -388.3% | — | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 AXSM | $11B | -59.8 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 LGND | $4B | -956.0 | 322.1 | 53.4 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
 ATNM | $38M | -1.0 | — | — | — | — | -110.6% | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See BHVN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BHVN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BHVN vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonBHVN — Frequently Asked Questions
Quick answers to the most common questions about buying BHVN stock.
What is Biohaven Ltd.'s P/E ratio?
Biohaven Ltd.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
What is Biohaven Ltd.'s ROE?
Biohaven Ltd.'s return on equity (ROE) is -310.8%. The historical average is -227.6%.
Is BHVN stock overvalued?
Based on historical data, Biohaven Ltd. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.